Category: News

TEAM FENFURO partcipated in Ninth Edition of PHD Chamber’s Annual International Trade Expo “Punjab International Trade Expo (PITEX) 2014  from 4-8 December’2014 at Amritsar, Punjab.The Government of Punjab was the ‘Host State’.

Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity, PCOS(ploycystic ovarian syndrome)  & General Health.

Team FENFURO participated in VIBRANT GUJARAT GLOBAL TRADE SHOW – 2015 held at The Exhibition Centre, Near Mahatma Mandir, Gandhinagar, Gujarat during 7^th to 13^th January, 2015.

Free catalogues/informative material were distributed among visitors for awareness of Diabetes and its complications, Obesity & General Health.

Poster Presentation on “CLINICAL EVALUATION OF FENFURO (FUROSTANOLIC SAPONINS) IN PATIENTS WITH TYPE-2 DIABETES”  at 6th World Congress of Diabetes India   held on 9^thto 12^thApril at Hotel ITC Grand Chola Convention Centre Chennai.

Patients with type 2 diabetes treated with insulin could be exposed to a greater risk of health complications including heart attack, stroke, cancer and eye complications a new study has found. 

Examining the UK Clinical Practice Research Datalink (CPRD) – data that characterizes about 10 percent of the UK population – a team of researchers from Cardiff University’s School of Medicine looked at the risk of death for patients taking insulin compared with other treatments designed to lower blood glucose levels in people with type 2 diabetes. 

The team’s epidemiological study found people have greater risk of individual complications associated with diabetes such as heart attack, stroke, eye complications and renal disease when compared with patients treated with alternative glucose-lowering treatments. 

“Insulin treatment remains the most longstanding blood-glucose-lowering therapies for people with type 2 diabetes, with its use growing markedly in recent years,” according to Professor Craig Currie from Cardiff University’s School of Medicine, who led the study. 

“However, with new diabetes therapies and treatments emerging there has been a new spotlight on treatments to ensure what the best and safest form of diabetes treatment is. 

“By reviewing data from CPRD between 1999 and 2011 we’ve confirmed there are increased health risks for patients with type 2 diabetes who take insulin to manage their condition,” he adds. 

The study adds to previous findings which identified potential health risks of insulin in this specific group of people. 

Initial concerns were first raised regarding the use of insulin in type 2 diabetes from a population-based study in Canada, which reported a three-fold increase in mortality. 

A similar study of people in UK primary care with type 2 diabetes treated with insulin also reported a 50 percent risk of increased mortality compared with another common treatment regimen. 

Professor Currie adds: “Patients currently being treated with insulin should not, under any circumstances, stop taking their medications, and it is important to emphasize that this report related to only type 2 diabetes which typically starts in older people who are overweight. 

“Each patient’s individual circumstances are different and treatment decisions are managed by their clinician with all of their medical history fully considered. 

“The vast majority of people who take insulin will experience no adverse effects and it remains a reliable and common form of treatment worldwide but this study shows that we need to investigate this matter urgently and the drug regulatory authorities should take interest in this issue. 

“Anyone who is concerned should speak to their GP first before taking any action on managing their condition.”

Source: http://jcem.endojournals.org/content/98/2/668.abstract?sid=e5e8ec61-0997-43bd-934b-d4894998abb9

Enlarged prostate gland is a common problem in the ageing males. It is also called Benign Prostatic Hyperplasia (BPH). The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. As the prostate gets bigger, it may squeeze or partly block the urethra. This often causes problems with urinating. The prevalence of histologically diagnosed prostatic hyperplasia increases from 8 percent in men aged 31 to 40, to 40 to 50 percent in men aged 51 to 60, to over 80 percent in men older than age 80.

Chemical Resources (CHERESO) has announced the acceptance of its patent (A novel process for extraction of Pygeum from indigenous resources) by USPTO (United States Patent & Trademarks Office), which extends the scope of phytotherapy in getting therapeutic relief from Benign Prostatic Hyperplasia (BPH). Pygeum is used as the main ingredient in PROSMAN, a first of its kind product to aid BPH treatment. PROSMAN has no side effects and is safe for consumption.
CHERESO is the proud owner of 9 international patents in the segment of blood glucose management, polycystic ovary syndrome (PCOS) management, prostate and men’s health etc. CHERESO is also having its own branded formulation for these applications.
Pygeum contains numerous beneficial bioactive constituents, including phytosterols, the most bioactive phytochemicals and beta-sitosterols, which exhibit anti-inflammatory action by inhibiting the production of prostaglandins in the prostate. Other Pygeum components include Ferulic acid esters, which reduce levels of prolactin and pentacyclic triterpenes by inhibiting an enzyme involved in inflammation and also help reduce edema. These bioactive components of Pygeum extract are believed to exert the most important therapeutic effect in the treatment of Benign Prostatic Hyperplasia (BPH). It helps in reduction of the volume of the prostate gland and also have considerable effects on urine retention and frequency, which are the major problems associated with BPH. PROSMAN will soon be launched in the market after completion of the ongoing clinical studies.
The news has come as a ray of hope for patients of BPH. PROSMAN will enable them to enjoy a hale and hearty life.